Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 69Thoracic 51Genitourinary 47Gynecologic 29Breast 28Head & Neck 23CNS 18Dermatologic 14Other hematologic neoplasm 13Endocrine 13Lymphoid 9NET 8Sarcoma 7Myeloid 5Tumor-Agnostic 4Plasma cell 3Other neoplasm 2Other solid neoplasm 1Other 1

Conditions

Advanced Solid Tumors 483Solid Tumor 446Advanced Solid Tumor 414Unspecified Adult Solid Tumor, Protocol Specific 362Solid Tumors 336Mesothelioma, Malignant 324Mesothelioma 289Solid Tumor, Adult 124Carcinoma, Non-Small-Cell Lung 122Retinoblastoma 117Lung Neoplasms 77Ovarian Neoplasms 75Melanoma 65Sarcoma 62Carcinoma, Renal Cell 59Stomach Neoplasms 58Pancreatic Neoplasms 58Neoplasms 53Esophageal Neoplasms 53Small Cell Lung Carcinoma 52Colorectal Neoplasms 52Hematopoietic and Lymphatic System Neoplasm 50Uterine Cervical Neoplasms 46Breast Neoplasms 46Solid Tumours 35Neoplasm Metastasis 35Advanced or Metastatic Solid Tumors 35Squamous Cell Carcinoma of Head and Neck 34Carcinoma, Hepatocellular 32Triple Negative Breast Neoplasms 31

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × Other solid neoplasm × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡